吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (2): 198-201.

吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响

何春玲¹, 邢文², 鲁柯兵³, 夏礼斌¹, 王安才²

¹皖南医学院弋矶山医院内分泌科,²老年医学科,³超声医学科,芜湖 241001,安徽

收稿日期:2012-12-12 修回日期:2012-12-12 发布日期:2013-02-28
通讯作者: 王安才,通信作者,男,教授,主任医师,硕士生导师,研究方向:老年心血管病临床与基础。 Tel: 0553-5739811 E-mail: yjswac@sina.com
作者简介:何春玲,女,主治医师,研究方向:内分泌与代谢性疾病。
基金资助:
皖南医学院中青年基金资助(WK2011F12)

Effects of pioglitazone combined with atorvastatin on lipids and endothelial function in patients of type 2 diabetes mellitus

HE Chun-ling¹, XING Wen², LU Ke-bing³, XIA Li-bin¹, WANG An-cai²

¹Department of Endocrinology,Yijishan Hospital,Wannan Medical College,Wuhu 241001,Anhui,China;
²Department of Gerontology;
³Department of Ultrasound,Wuhu 241001,Anhui,China

Received:2012-12-12 Revised:2012-12-12 Published:2013-02-28

摘要/Abstract

摘要： 目的: 观察吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响。方法: 选择2型糖尿病患者65例,随机分为对照组30例(A组),接受常规降糖药治疗和阿托伐他汀 10 mg/d;实验组35例(B组),在对照组基础上加用吡格列酮 15 mg/d,两组患者分别于治疗前、用药12周后检测血糖、糖化血红蛋白、血脂、血浆一氧化氮(NO)、内皮素-1(ET-1)的浓度、肱动脉内径变化率(FMD)。结果: 治疗后两组患者的血糖水平均较治疗前明显降低,与治疗前比较差异有统计学意义(P<0.01),但两组间比较差异无统计学意义(P>0.05)。两组患者ET-1水平有所降低(P<0.05),血浆NO水平和FMD均明显升高,与治疗前比较差异均有统计学意义(P<0.01);B组NO的升高水平和FMD较A组明显,两组比较差异均有统计学意义(P<0.05)。治疗后两组患者体重指数均有所改善(P<0.05,P<0.01)。结论: 吡格列酮联用阿托伐他汀能够更有效降低患者血脂水平,改善2型糖尿病患者血管内皮功能。

关键词: 吡格列酮, 2型糖尿病, 内皮功能

Abstract: AIM: To observe the effects of pioglitazone combined with atorvastatin on lipids and endothelial function in patients of type 2 diabetes mellitus. METHODS: 65 cases of type 2 diabetes patients were randomly divided into two groups, 30 cases were divided into control group (Group A), receiving routine hypoglycemic therapy with atorvastatin 10 mg/d; the experimental group (Group B), 35 cases on the basis of the control group with pioglitazone 15 mg/d.The levels of blood glucose, Glycated hemoglobin, lipids, nitric oxide (NO) , endothelin -1 (ET-1) and the change rate of brachial artery flow mediated dilatation(FMD)were assessed before and after 12 weeks of the treatment. RESULTS: Compared with pre-treatment,the levels of blood glucose after treatment were significantly decreased in two groups (P<0.01). there was no significant difference between two groups (P>0.05). The ET-1 levels in two groups were decreased (P<0.05), and the levels of nitric oxide (NO) and FMD were increased in two groups,compared with pre-treatment,there was significant difference(P<0.01).However, the levels of nitric oxide (NO) and the change rate of brachial artery flow mediated dilatation(FMD) in Group B were higher than those in Group A, there was significant difference in two groups(P<0.05).After treatment,the BMI was improved in patients of two groups (P<0.05, P<0.01).CONCLUSION: Pioglitazone combined with atorvastatin can adjust blood lipids and improve the function of vascular endothelium in type 2 diabetes mellitus

Key words: Pioglitazone, Type 2 diabetes mellitus, Endothelial function

中图分类号:

R578.1

何春玲, 邢文, 鲁柯兵, 夏礼斌, 王安才. 吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响[J]. 中国临床药理学与治疗学, 2013, 18(2): 198-201.

HE Chun-ling, XING Wen, LU Ke-bing, XIA Li-bin, WANG An-cai. Effects of pioglitazone combined with atorvastatin on lipids and endothelial function in patients of type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 198-201.

参考文献

[1] 韩勇. 阿托伐他汀改善高血压合并高血脂患者的血管内皮功能[J].中华高血压杂志,2008,16(4):368-369.
[2] Patel CB, De Lemos JA, Wyne KL, et al.Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism[J].Diab Vasc Dis Res, 2006,3(2):65-71.
[3] Celermajer DS, Sorensen KE,Gooch VM, et al.Non-invasivedeterction of endothelial dysfunction in children and adults at risk of athetosclerosis[J].Lancet,1992,340(8828):1111-1115.
[4] Sena CM, Nunes E, Louro T, et al.Endothelial dysfunction in type 2 diabetes: effect of antioxidants[J].Rev Port Cardiol, 2007,26(6):609-619.
[5] 陈晓艺,王金萍,李保启,等. 初诊2型糖尿病患者血管内皮功能受损的超声评价[J].安徽医学,2012,33(5):588-590.
[6] Widyantoro B, Emoto N, Nakayama K, et al.Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition[J]. Circulation,2010;121(22):2407-18.
[7] Campbell IW, Mariz S.Beta-cell preservation with thiazolidinediones[J].Diabetes Res Clin Pract,2007,76(2):163-176.
[8] 杜瑞琴,李宏亮,杨文英,等.吡格列酮对胰岛α细胞胰岛素抵抗的影响[J].中华内分泌代谢杂志,2008,24(1):29-33.
[9] Adel A, Abdel-Salam Z, Nammas W.Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study[J]. J Clin Hypertens (Greenwich), 2010,12(10):820-825.
[10] Elmadhun NY, Lassaletta AD, Chu LM, et al.Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome[J]. J Thorac Cardiovasc Surg, 2012,44(6):1486-1493.
[11] 李银,黎敬锋,李世光,等,不同剂量阿托伐他汀对2型糖尿病患者心血管并发症的影响[J].中国临床药理学与治疗学,2012,17(9):1033-1037.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[5]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[6]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[7]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[8]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[9]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[10]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[11]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.
[12]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.
[13]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[14]	徐永霞, 谢明珠, 宫牧雪, 黄嘉莹, 赵丽, 朱德发. 25羟维生素D对老年2型糖尿病患者胰岛β细胞功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1021-1026.
[15]	赵海玲, 张浩军, 赵婷婷, 严美花, 董晞, 马亮, 李平. PNPLA2基因多态性与中国汉族2型糖尿病患者缺血性脑卒中的相关性研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 664-669.